Management of metastatic esophagogastric junction adenocarcinoma

Abstract

The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents. Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options. In this review, we summarized previous evidences of cytotoxic agents widely used worldwide, and updated recent developments of molecular targeted drugs, and immune checkpoint inhibitors.

Keywords

Esophagogastric junction / adenocarcinoma / advanced / molecular targeted drug / immune checkpoint inhibitor / immunotherapy

References

[1] Siewert JR.Classification of adenocarcinoma of the oesophagogastric junction..Br J Surg1998;85:1457-9

[2] Stein HJ,Siewert JR.Cancer of the esophagogastric junction..Surg Oncol2000;9:35-41

[3] Gronnier C,Mariette C.Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: what are the current options?.J Visc Surg2012;149:e23-33

[4] Tajima Y,Makino R,Masuda Y,Kato M,Kusano M.Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach..Br J Cancer2007;96:631-8 PMCID:PMC2360051

[5] Li-Chang HH,Ng Y,Kong E,Jones SJ,Schaeffer DF.Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas..BMC Cancer2015;15:32 PMCID:PMC4322811

[6] Bang YJ,Feyereislova A,Shen L,Lordick F,Omuro Y,Aprile G,Hill J,Ruschoff J.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial..Lancet2010;376:687-97

[7] Wilke H,Van Cutsem E,Bodoky G,Hironaka S,Lipatov O,Cunningham D,Komatsu Y,Emig M,Ferry D,Schwartz JD.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial..Lancet Oncol2014;15:1224-35

[8] Wagner AD,Grothe W,Grothey A,Fleig WE.Chemotherapy for advanced gastric cancer..Cochrane Database Syst Rev2017;8:CD004064

[9] Cancer Genome Atlas Research Network.Comprehensive molecular characterization of gastric adenocarcinoma..Nature2014;513:202-9 PMCID:PMC4170219

[10] Cancer Genome Atlas Research Network.Integrated genomic characterization of oesophageal carcinoma..Nature2017;541:169-75 PMCID:PMC5651175

[11] Ajani JA,Tjulandin SA,Chao Y,Majlis A,Van Cutsem E.Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma..J Clin Oncol2005;23:5660-7

[12] Cunningham D,Rao S,Nicolson M,Middleton G,Oates J.Capecitabine and oxaliplatin for advanced esophagogastric cancer..N Engl J Med2008;358:36-46

[13] Koizumi W,Hara T,Akiya T,Miyashita K,Kobayashi O,Toh Y,Takagi S,Yanaoka K,Takeuchi M.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial..Lancet Oncol2008;9:215-21

[14] Fuchs CS,Yong CJ,Passalacqua R,Safran H,Aprile G,Melichar B,Topuzov E,Chau I,Sivanandan C,Koshiji M,Liepa AM,Schwartz JD.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial..Lancet2014;383:31-9

[15] Cunningham D,Smyth EC,Allum WH,Stevenson L,Alderson D,Griffin SM,Coxon FY,Darby S,Blazeby JM.Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial..Lancet Oncol2017;18:357-70

[16] Gerber HP.Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies..Cancer Res2005;65:671-80

[17] Ohtsu A,Van Cutsem E,Sawaki A,Lim HY,Wu J,Starnawski M.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study..J Clin Oncol2011;29:3968-76

[18] Hecht JR,Qin SK,Xu JM,Jeziorski K,Hoff PM,Salman P,Protsenko SA,Buyse M,Houe V,Kaneko T,Khan-Wasti S,Press MF.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial..J Clin Oncol2016;34:443-51

[19] Satoh T,Chung HC,Doi T,Tsuji A,Li J,Miwa H,Chung IJ,Feng JF,Kobayashi M,Bang YJ.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study..J Clin Oncol2014;32:2039-49

[20] Bokemeyer C,Hartmann JT,Schuch G,Celik I,Koralewski P.Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study..Ann Oncol2011;22:1535-46

[21] Van Cutsem E,Lang I,Nowacki MP,Shchepotin I,Cunningham D,Schlichting M,Celik I,Ciardiello F.Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status..J Clin Oncol2011;29:2011-9

[22] Vermorken JB,Rivera F,Kawecki A,Erfan J,Kienzer HR,Peyrade F,Vynnychenko I,Bokemeyer C,Amellal N.Platinum-based chemotherapy plus cetuximab in head and neck cancer..N Engl J Med2008;359:1116-27

[23] Pirker R,Szczesna A,Krzakowski M,Vynnychenko I,Yu CT,Roh JK,O'Byrne K,Eberhardt W,Emig M.Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial..Lancet2009;373:1525-31

[24] Lordick F,Chung HC,Oh SC,Kurteva G,Moiseyenko VM,Park JO,Celik I,Melezinkova H.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial..Lancet Oncol2013;14:490-9

[25] Douillard JY,Cassidy J,Burkes R,Humblet Y,Cunningham D,Rivera F,Ruff P,Smakal M,Rother M,Wolf M.Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study..J Clin Oncol2010;28:4697-705

[26] Waddell T,Cunningham D,Okines AF,Wotherspoon A,Middleton G,Ferry D,Crosby T,Smith D,Iveson T,Slater S,Barbachano Y.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial..Lancet Oncol2013;14:481-9

[27] Catenacci DVT,Davidenko I,Al-Batran SE,Tjulandin S,Karaszewska B,Tejani MA,Tehfe M,Turkington C,Ang A,Hoang T,Cunningham D.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet Oncol2017;18:1467-82

[28] Spigel DR,O'Byrne K,Mocci S,Shames DS,Yu W,Mok T.Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung..J Clin Oncol2017;35:412-20

[29] Shah MA,Lordick F,Chen M,Bruey JM,McCaffery I,Phan S.Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial..JAMA Oncol2017;3:620-7 PMCID:PMC5824210

[30] Ohtsu A,Bai YX,Chung HC,Sahmoud T,Yeh KH,Muro K,Ferry D,Al-Batran SE,Costantini C,Lebwohl D.Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study..J Clin Oncol2013;31:3935-43

[31] Thuss-Patience PC,Ohtsu A,Ajani JA,Mansoor W,Bodoky G,Phillips GDL,Harle-Yge ML,Kang YK.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study..Lancet Oncol2017;18:640-53

[32] Catenacci DV.Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity..Mol Oncol2015;9:967-96 PMCID:PMC4402102

[33] Ajani JA,Sano T,Fan D.Gastric adenocarcinoma..Nat Rev Dis Primers2017;3:17036

[34] Muro K,Shankaran V,Catenacci D,Eder JP,Le DT,McRee AJ,Pathiraja K,Emancipator K,Koshiji M.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial..Lancet Oncol2016;17:717-26

[35] Kang YK,Satoh T,Chao Y,Chung HC,Muro K,Yeh KH,Oh SC,Tamura T,Hamamoto Y,Chin K,Minashi K,Tsuda M.Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;390:2461-71

[36] Le DT,Calvo E,Ascierto PA,Ott PA,Jaeger D,Braud FGD,Christensen O,Lin CS.Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 study..J Clin Oncol2016;34 suppl 4:abstr6

[37] Janjigian YY,Calvo E,Ascierto PA,Ott PA,Jaeger D,Braud FGD,Tschaika M,Lin C-S C.CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC)..J Clin Oncol2016;34 suppl 15:abstr4010

[38] Janjigian YY,Aucoin J-S J,Boku N,Cleary JM,Franke FA,Roca EL,Li M.Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer..J Clin Oncol2017;35 suppl 4:abstrTPS213

[39] Herbst RS,Kowanetz M,Hamid O,Sosman JA,Powderly JD,Kohrt HE,Lawrence DP,Leabman M,Mokatrin A,Hegde PS,Chen DS.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients..Nature2014;515:563-7 PMCID:PMC4836193

[40] Lipson EJ,Drake CG,Taube JM,Xu H,Pons A,Pardoll DM,Topalian SL.Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody..Clin Cancer Res2013;19:462-8 PMCID:PMC3548952

[41] Lote H,Chau I.PD-1 and PD-L1 blockade in gastrointestinal malignancies..Cancer Treat Rev2015;41:893-903

[42] Zhang M,Liu H,Zhao S,Wang Y.The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients..Sci Rep2016;6:37933 PMCID:PMC5124943

[43] Gopalakrishnan V,Nezi L,Andrews MC,Prieto PA,Hoffman K,Cogdill AP,Hudgens CW,Manzo T,Cotechini T,Chen WS,Szczepaniak Sloane R,Jiang H,Shpall EJ,Alousi AM,Shelburne S,Okhuysen PC,Swennes AG,Marcelo Riquelme Sanchez E,Le Chatelier E,Pons N,Haydu LE,Gardner JM,Hu J,Tsujikawa T,Tawbi H,Hwu WJ,Woodman SE,Davies MA,Hwu P,Zhang J,Cooper ZA,Daniel CR,Petrosino JF,Sharma P,Jenq RR.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients..Science2018;359:97-103 PMCID:PMC5827966

[44] Vetizou M,Daillere R,Waldschmitt N,Rusakiewicz S,Roberti MP,Poirier-Colame V,Becharef S,Golden E,Eberl G,Ginhoux F,Yamazaki T,Enot DP,Nigou J,Eggermont A,Chachaty E,Robert C,Kroemer G,Boneca IG,Chamaillard M.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota..Science2015;350:1079-84 PMCID:PMC4721659

[45] Routy B,Derosa L,Alou MT,Fluckiger A,Rauber C,Fidelle M,Poirier-Colame V,Klein C,Mondragon L,Qu B,Clemenson C,Masip JR,Brosseau S,Richard C,Levenez F,Quinquis B,Ryffel B,Gonin P,Deutsch E,Ghiringhelli F,Goldwasser F,Hellmann MD,Raoult D,Kroemer G.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors..Science2018;359:91-7

[46] Nguyen LT.Clinical blockade of PD1 and LAG3--potential mechanisms of action..Nat Rev Immunol2015;15:45-56

[47] Anderson AC,Kuchroo VK.Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation..Immunity2016;44:989-1004 PMCID:PMC4942846

[48] Martinet L.Balancing natural killer cell activation through paired receptors..Nat Rev Immunol2015;15:243-54

[49] Van Cutsem E,Kang YK,Tebbutt NC,Peng Yong W,Delmar P,Shah MA.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial..J Clin Oncol2012;30:2119-27

[50] Bruzzi JF,Truong MT,Hofstetter WL,Correa AM,Ajani JA,Fukami N.Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy..Cancer2007;109:125-34

[51] Bang YJ,Lee KW,Song EK,Kim YH,Chun HG,Fielding A,Hodgson D,Yin X.Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer..J Clin Oncol2015;33:3858-65